Bio News
The US Food and Drug Administration (FDA) approved Priovant Therapeutics’ Lisraya to treat dermatomyositis in adults. Lisraya is a once-daily pill and the first targeted therapy approved for dermatomyositis. Priovant is pursuing label expansion through a phase 3 trial in noninfectious uveitis and a late-stage study in cutaneous sarcoidosis.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
